July 15, 2025
Cheaper versions of obesity medications like Ozempic and Wegovy may become available in Canada by January, as Novo Nordisk's market exclusivity ends. These medications, containing semaglutide, are used to regulate blood sugar and appetite. With 33% of Canadians being obese in 2023, the introduction of generic versions could make these treatments more accessible.
Full article link